19815 Bay Branch Rd
Andalusia, Alabama 36420
(334) 222-2525



Facebook    

 

SCAMHC is an approved Mental Health site for the National Health Service Corps Loan Repayment program.  Find out the program details and see if you qualify by visiting: http://nhsc.hrsa.gov/

SCAMHC is an Equal Opportunity Provider and Employer and maintains a Drug-Free Workplace


powered by centersite dot net
Alzheimers Disease and other Cognitive Disorders
Resources
Basic Information
Introduction & Causes of Cognitive DisordersDementiaAlzheimer's DiseaseOther Cognitive DisordersDementia Coping Skills & Behavior ManagementTraumatic Brain Injury (TBI)Conclusion and Resources
More InformationLatest News
Lifestyle Changes Might Prevent or Slow DementiaSevere Headaches Plague Vets With Traumatic Brain InjuriesSticky Brain 'Plaques' Implicated in Alzheimer's Again'Making the Best of It': Families Face the Heavy Burden of Alzheimer'sCognitive Decline Linked to Visual Field VariabilityAlzheimer's Deaths Jump 55 Percent: CDCLife Expectancy Slighter Shorter With Parkinson's, DementiaLow Body Mass Index Not Risk Factor for Alzheimer's DiseaseThin People Not More Prone to Alzheimer's, Study FindsWives, Daughters Shoulder Most of Alzheimer's Care BurdenGene Mutation May Speed Alzheimer's DeclineSilent Seizures May Contribute to Alzheimer's Pathology'Silent' Seizures Tied to Alzheimer's SymptomsPsychiatric Scars of Wartime Brain Injury May Linger for YearsMany Patients With Alzheimer's Disease Discontinue AChEIsMicrovascular Endothelial Dysfunction Can Predict DementiaAntipsychotic Medication Use Can Be Reduced in Dementia PatientsPast Psychiatric Disorders Do Not Raise Risk of Alzheimer's DiseasePast Psychiatric Ills Don't Raise Alzheimer's Risk: StudyXanax, Valium May Boost Pneumonia Risk in Alzheimer's PatientsSGA Prescribing Higher for Veterans With PTSD/DementiaDrug Tied to Dementia Risk Overprescribed to Seniors: StudyProton Pump Inhibitor Use Ups Pneumonia Risk in DementiaVitamin E, Selenium Supplements Won't Curb Men's Dementia RiskDizzy Spells in Middle-Age Tied to Dementia Risk LaterFive Million American Seniors Now Living With Alzheimer'sStudy: Gene Test Needed Before Using Alzheimer's Drug 'Off-Label'Annual Death Toll From Alzheimer's Nearly Doubles in 15 YearsImmune Disorders Such as MS, Psoriasis May Be Tied to Dementia RiskIs Need for More Sleep a Sign of Pending Dementia?Unhealthy in Middle Age, Dementia in Old Age?HRT Won't Lower Women's Alzheimer's Risk, Study FindsReview Links Albuminuria to Cognitive Impairment, DementiaCan Air Pollution Heighten Alzheimer's Risk?Bilingual People May Have an Edge Against Alzheimer'sBusy Minds May Be Better at Fighting DementiaDementia May Be Exacerbated by Hospital-Related DeliriumLink Seen Between Concussions and Alzheimer'sContinuing Warfarin Protective After Diagnosis of DementiaDoes Living Near Major Roads Boost Dementia Risk?Caregiver Phone Support Ups Use of Community ResourcesAntipsychotic Drugs May Up Risk of Early Death in Alzheimer's PatientsIs Dementia in Older Women Tied to 20-Year Rate of Weight Loss?Better Sleep May Signal Recovery From Brain Injuryβ-Blockers May Not Be Appropriate for Dementia PatientsTest Predicting Alzheimer's Would Be Welcome, Survey FindsWhether Statins Cut Alzheimer's Risk May Depend on Gender, RaceBeta Blockers May Not Be Best Heart Drugs for Dementia PatientsAlzheimer's Patients' Use of Painkilling Patches Cause for ConcernYoung Adults With Head Trauma May Have Higher Risk of Jail Time
Questions and AnswersVideosLinksBook Reviews
Related Topics

Aging & Geriatrics
Memory Problems
Elder Care

Many Patients With Alzheimer's Disease Discontinue AChEIs


HealthDay News
Updated: Apr 26th 2017

new article illustration

WEDNESDAY, April 26, 2017 (HealthDay News) -- Discontinuation of acetylcholinesterase inhibitors (AChEIs) for treatment of Alzheimer's disease is common, with adverse effects and cost cited as major factors, according to a study published recently in the Journal of the American Geriatrics Society.

Noll L. Campbell, Pharm.D., from the Purdue University School of Pharmacy in West Lafayette, Ind., and colleagues randomized 196 older adults with a diagnosis of possible or probable Alzheimer's disease who were initiating treatment with an AChEI to one of three AChEIs (1:1:1) for 18 weeks.

In the intent to treat analysis, the researchers found that discontinuation rates at the end of 18 weeks were 38.8 percent for donepezil, 53.0 percent for galantamine, and 58.7 percent for rivastigmine (P = 0.063). Adverse events explained 73.1 percent of discontinuation, while cost explained 25.4 percent. More than 81 percent of participants reported adverse events, but rates were similar between groups.

"This pragmatic comparative trial showed high rates of adverse events and cost-related nonadherence with AChEIs," the authors write.

Abstract
Full Text (subscription or payment may be required)